Phase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based Antiretroviral Therapy in Women With Fat Accumulation

Trial Profile

Phase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based Antiretroviral Therapy in Women With Fat Accumulation

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs Raltegravir (Primary) ; HIV protease inhibitors; Non-nucleoside reverse transcriptase inhibitors
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms IISP-Raltegravir
  • Most Recent Events

    • 16 Feb 2017 Results (n=37) assessing effect of switching from protease and non-nucleotide reverse transcriptase inhibitors-based regimens to raltegravir-based regimens on biomarkers of liver steatosis and metabolic syndrome in women, presented at the 24th Conference on Retroviruses and Opportunistic Infections.
    • 06 Mar 2013 Biomarker results presented at the 20th Conference on Retroviruses and Opportunistic Infections.
    • 20 Jul 2011 Results presented at the 6th International AIDS Society Conference on HIV Pathogenesis and Treatment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top